11 stories mentioning HKG:1877Updated 13d ago
Every FINWIRES story that references HKG:1877, newest first.
Shanghai Junshi Biosciences (SHA:688180, HKG:1877) said Shanghai Tanying Investment Partnership is planning to reduce its shareholding in the company by up to over 20.5 million shares.Shanghai Tanying Investment Partnership holds 38.9 million China-listed shares in the company, according to a Monday Hong Kong bourse filing.
Shanghai Junshi Biosciences (SHA:688180, HKG:1877) estimated related-party transactions totaling 35.0 million yuan with TopAlliance Biosciences and its subsidiaries.The transactions involve product sales, service provisions and acceptance of services, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade on the Hong Kong bourse.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) booked an attributable profit of 25.5 million yuan in the first half of 2026, returning from a loss of 413.4 million yuan a year prior, a Wednesday Hong Kong bourse filing said.Earnings per share stood at 0.02 yuan, compared with a loss per share of 0.42 yuan in the year-ago period.Revenue for the interim period increased 45% to 1.70 billion yuan from 1.17 million yuan in the corresponding period of the last year.
Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) shareholder, He Ming, sold 882,600 shares for 33.5 million yuan, according to a Tuesday filing.The shares were sold through centralized bidding at prices ranging from 35.76 yuan to 40.34 yuan each between July 3 and Aug. 10.Following the sale, He Ming held 2.65 million shares, or 0.2579% of the company's total share capital, down from 0.3440%.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) completed the issuance of its 2026 second tranche of technology innovation bonds and received the proceeds on Tuesday, according to a Wednesday Hong Kong bourse filing.The company issued the three-year bonds with a total principal amount of 300 million yuan at an interest rate of 2.59%.The bonds will mature on July 22, 2029, the filing showed.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) agreed to license JS005 to Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) for the greater China region, according to a Wednesday filing with the Hong Kong bourse.The company will receive an upfront payment of 215 million yuan, plus a further 1.13 billion yuan in milestone-related payments.Junshi Biosciences will also receive royalty payments once the drug is commercialized in the greater China region.JS005, also known as roconkibart, is a treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis.
Hong Kong stocks fell Monday as a technology-led selloff gathered pace after stronger-than-expected U.S. jobs data and renewed military tensions between Israel and Iran weighed on sentiment.The Hang Seng Index shed 1.2%, or 304.89 points, to close at 24,657.06, while the Hang Seng China Enterprises Index lost 1.1%, or 95.27 points, to finish at 8,341.36.The robust U.S. jobs report prompted traders to increase bets on a Federal Reserve rate hike later this year, triggering a selloff in technology stocks.Markets are now pricing in a 72% probability of a rate hike by December, according to CME Group's FedWatch tool.Meanwhile, Israel and Iran exchanged strikes for the first time since their ceasefire took effect, raising fresh doubts about the durability of the truce.The escalation came after U.S. President Donald Trump said Sunday that renewed military action by either side would not derail Washington's peace talks with Tehran.Brent crude rose more than $4 a barrel on Monday, extending gains as renewed hostilities heightened concerns over regional stability.Shanghai Junshi Biosciences (HKG:1877, SHA:688180) closed 3% lower after saying it will contribute intellectual property and pre-clinical oncology assets to a newly established joint venture, Shanghai OnTarget Biopharmaceuticals, in exchange for a 14.55% stake.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint venture, according to a Friday Hong Kong bourse filing.In return, the biotech company will receive a 14.55% stake in the venture, Shanghai OnTarget Biopharmaceuticals.The contributed assets were valued at about 53.1 million yuan, with the joint venture issuing 250,000 yuan of new registered capital to Junshi as consideration.Junshi expects to record an unaudited gain of about 52.1 million yuan upon completion of the transaction.The joint venture is developing multi-specific antibody and antibody-conjugate technologies for oncology treatments.Hong Kong-listed shares of the firm were down more than 2% in Monday's late-morning trade.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) said its cancer therapy toripalimab met the main goal of a phase 3 study in lung cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in late morning trade Wednesday.Based on the final analysis of the trial, the drug met the primary endpoints of event-free survival and major pathological response in subjects with stage II-III non-small cell lung cancer, the firm said.The company now plans to seek regulatory approval to expand the drug's coverage from perioperative treatment of patients with resectable stage III non-small cell lung cancer to those with stage II-III of the disease.
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a drug registration certificate from China's National Medical Products Administration for a new indication for toripalimab, according to a Hong Kong bourse filing on Thursday.The pharmaceutical company's Shanghai shares dropped by less than 4%, while Hong Kong shares fell by less than 2% during Friday's morning trade.The drug, which trades as Tuoyi, will be allowed for the treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma in combination with disitamab vedotin, an antibody drug conjugate developed by RemeGen (HKG:9995, SHA:688331).
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) said a major shareholder did not sell any shares as its reduction plan expired, according to an April 10 Hong Kong bourse filing.Hong Kong-listed shares of the firm were up nearly 5% in Monday midday trade.Shanghai Tanying Investment, which held about 5.8% of the company, had planned to reduce up to 2% of its stake between January and April.
